Comera Life Sciences Debuts in the Red

by | May 20, 2022

The maker of self-injectible biologics closed down 9% on the day. An updated look at deSPAC count and redemption rates.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

Comera Life Sciences (CMRA) deSPACs today

Self-ingestible biologics specialist Comera Life Sciences CMRA) deSPAC’d today from OTR Acquisition Corp (OTRA). Low float deSPAC: 9.8M shares redeemed (94%). Shares closed at $8.85, down 9%.

deSPAC Count and Redemption Update

As we prepare for the last week of May, here’s an update on deSPAC and redemption stats. In addition to CMRA, three other SPACs have made it out: Eve (EVEX), NuScale Power (SMR), and SAITECH (SAI). All are trading below $10. Redemptions look like they are trending back up: average redemption rate is 75% month-to-date–down from 74% in April and 29% in the year ago.

Source: Boardroom Alpha

deSPAC Heat Map

Shares of the Southeast Asian delivery, mobility and financial services app Grab Holdings (GRAB) are showing strong momentum, jumping 24% yesterday on the company’s earnings upside and upward revision to guidance. Urban air mobility specialist Eve Holding (EVEX) is another upward mover, having been volatile since its deSPAC on May 10th. Shares closed up 6% today.

Source: Boardroom Alpha

Elsewhere in SPACs

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

<a href="https://www.boardroomalpha.com/author/joanna/" target="_self">Joanna Makris</a>

Joanna Makris

Joanna has been analyzing and investing in emerging technologies for over two decades, having led the Technology, Media, and Telecom research at several global investment banks, including Mizuho Securities and Canaccord Genuity. Navigating stock market volatility since it all began in 2000. Banjo player, artist, and frittata-maker.

Know Who Drives Return

Objective, data-driven assessments for every public company director and officer.

Learn More

SPAC Analytics & Database

Comprehensive research and analytics on every SPAC, sponsor, and deal. Real-time alerts, yields, red flags, filings, investors, and much more. API access to institutional grade SPAC database.

Learn More

Monthly SPAC Review

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

SPAC Research & Analysis

SPAC Daily: Return of the IPO

Aug 5, 2022

Return of the SPAC IPOs after a hiatus, August new deals are off to a hot start, and the rest of the day’s news in SPACs.

Know Who Drives Return Podcast

Investing in SPACs for Yield with Jonathan Browne from Robinson Capital

Oct 4, 2021

Jonathan Browne from Robinson Capital joins Boardroom Alpha’s David Drapkin to talk about SPAC arbitrage. Robinson Capital’s SPAX ETF launched in June of 2021 and is an actively managed exchange-trade fund (ETF) that invests in Special Purpose Acquisition Companies (SPACs), also known as blank check companies. SPAX seeks to provide total return while minimizing downside risk.

SPACs, FOMO, and Tail Risk – Matthew Tuttle Captures the Momentum

Sep 24, 2021

Matthew Tuttle from Tuttle Capital joins David Drapkin to talk about SPACs, FOMO, and tail risk. Tuttle Capital’s thematic and actively managed ETFs are taking advantage of the SPAC craze, everybody’s FOMO (fear of missing out), and protecting the downside tail risk.

Kyle Bransfield and Ruben Minski on the Union Acquisition II / Procaps SPAC Deal

Sep 16, 2021

Boardroom Alpha’s David Drapkin welcomes Union Acquisition II CEO Kyle Bransfield and Procaps CEO Ruben Minski to the podcast. The deal goes to vote on September 22, 2021 and ex-redemption on September 17, so this will be one of shareholders’ last opportunities to hear from the team before deciding to redeem or go long alongside Kyle and Ruben.

Sarcos CEO Ben Wolff on Robotics and SPACs

Sep 9, 2021

Ben Wolff, CEO of Sarcos, talks to Boardroom Alpha’s David Drapkin about robots, SPACs, and why investors should be looking at Sarcos as an opportunity to invest.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.